Today is #WorldKidneyDay, celebrated to raise awareness of the importance of good kidney health and the significant impact of kidney disease, the 10th leading cause of death globally. Mironid is working to transform the treatment landscape for patients with rare kidney disease. Our lead asset is a first-in-class small molecule LoAc® which directly targets the […]
Our CEO will be in Barcelona from 18-20 March at the annual BIO-Europe Spring conference, an opportunity to engage with the broader life science community and network with peers and collaborators. If you would like to meet Neil next week, please get in touch at: enquiries@mironid.com […]
Today is Rare Disease Day Join us at Mironid and #LightUpForRare to raise awareness of the 300 million people worldwide living with a rare disease, including Autosomal Dominant Polycystic Kidney Disease #ADPKD, the most common hereditary kidney disorder. The Rare Disease Day campaign is aimed at increasing access to diagnosis and treatment for people affected […]
#rarediseaseday is in 2 days! At Mironid, we are committed to transforming the treatment landscape for patients with Autosomal Dominant Polycystic Kidney Disease and other rare kidney diseases through novel scientific approaches. ADPKD is a rare genetic disorder characterized by the formation of multiple fluid-filled cysts in the kidneys. These cysts can lead to kidney […]
We are delighted to welcome Allister Williams to Mironid as our new Head of Programme Management. Allister joins the team with a wealth of knowledge in the biopharma space, including strong drug development expertise in clinical and preclinical programmes. Prior to joining Mironid, Allister was Associate Director, Preclinical at Beckley Psytech, before which he was […]
Read more de Mironid appoints Allister Williams as Head of Programme Management
Mironid’s CEO, CSO and CMO will be attending the J.P. Morgan Healthcare Conference from 8-11 January in San Francisco, CA. If you would like to connect, please get in touch at: enquiries@mironid.com […]
Our Chief Medical Officer, Cass Kelleher spoke to In Vivo about her role at Mironid, the unmet medical need in ADPKD and the potential impact of our LoAc® small molecules in development for the treatment of ADPKD. Read the full Q&A here: https://invivo.citeline.com/IV148658/Mironid-On-Reducing-The-Burden-Of-Polycystic-Kidney-Disease […]